Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 20/20 | 1.00 |
| ▸ | HCK | P08631 | 17/20 | 1.00 |
| ▸ | KDR | P35968 | 16/20 | 1.00 |
| ▸ | SRC | P12931 | 14/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 0.83 |
| ▸ | RET | P07949 | 1/20 | 0.83 |
| ▸ | KIT | P10721 | 1/20 | 0.83 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.83 |
| ▸ | TEK | Q02763 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589852 | 0.92 | LCK (0.84) | LCKHCKKDRSRCABL1 | |
| SCHEMBL3590297 | 0.91 | LCK (1.00) | LCKHCKKDRSRCABL1 | |
| SCHEMBL3590786 | 0.87 | LCK (0.85) | LCKHCKKDRSRCABL1 | |
| SCHEMBL3593572 | 0.85 | LCK (0.81) | LCKHCKKDRSRCABL1 | |
| SCHEMBL3593575 | 0.85 | LCK (0.81) | LCKHCKKDRSRCABL1 | |
| SCHEMBL3588491 | 0.85 | LCK (0.85) | LCKHCKKDRSRCABL1 | |
| SCHEMBL3587939 | 0.84 | LCK (0.73) | LCKHCKKDRSRCABL1 | |
| SCHEMBL3580655 | 0.83 | LCK (0.77) | LCKHCKKDRSRCABL1 | |
| SCHEMBL3585123 | 0.82 | LCK (0.74) | LCKHCKKDRSRCABL1 | |
| SCHEMBL3591907 | 0.82 | LCK (0.68) | LCKHCKKDRSRCABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | LCK 1/4885HCK 42/4885KDR 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.